# Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

Source: https://onco.cc/trials/nct07510815/  
OnCo record `nct07510815` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide in mesothelioma, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma is a phase 1/2 interventional study registered as NCT07510815 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide. Conditions listed: Malignant Pleural Mesotheliomas. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07510815
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Nonrandomized, Biomarker-Guided Study of Locoregional Allogeneic Dual-Target Mesothelin (MSLN) / Fibroblast Activation Protein (FAP) Chimeric Antigen Receptor Natural Killer Cells in Adults With Unresectable, Recurrent, or Refractory Pleural or Peritoneal Mesothelioma
- Sponsor: Beijing Biotech
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07510815: https://clinicaltrials.gov/study/NCT07510815

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [EB-MF-CAR-NK-01](https://onco.cc/drugs/eb-mf-car-nk-01/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07510815.json